ERBB2 and neoplasm: Prosigna® molecular subtyping was compared with local and two central (C1 and C6) molecular-like subtypes relying on both IHC (HRs, HER2, Ki-67) subtyping and IHC + tumor grade (IHC+G) subtyping.